JP2016510591A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510591A5
JP2016510591A5 JP2015559038A JP2015559038A JP2016510591A5 JP 2016510591 A5 JP2016510591 A5 JP 2016510591A5 JP 2015559038 A JP2015559038 A JP 2015559038A JP 2015559038 A JP2015559038 A JP 2015559038A JP 2016510591 A5 JP2016510591 A5 JP 2016510591A5
Authority
JP
Japan
Prior art keywords
cancer
mutation
inhibitor
detecting
akt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015559038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510591A (ja
JP6669500B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/017948 external-priority patent/WO2014130923A2/en
Publication of JP2016510591A publication Critical patent/JP2016510591A/ja
Publication of JP2016510591A5 publication Critical patent/JP2016510591A5/ja
Application granted granted Critical
Publication of JP6669500B2 publication Critical patent/JP6669500B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015559038A 2013-02-25 2014-02-24 薬物耐性akt変異体を検出し治療するための方法及び組成物 Expired - Fee Related JP6669500B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361769108P 2013-02-25 2013-02-25
US61/769,108 2013-02-25
PCT/US2014/017948 WO2014130923A2 (en) 2013-02-25 2014-02-24 Methods and compositions for detecting and treating drug resistant akt mutant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019088252A Division JP2019176858A (ja) 2013-02-25 2019-05-08 薬物耐性akt変異体を検出し治療するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2016510591A JP2016510591A (ja) 2016-04-11
JP2016510591A5 true JP2016510591A5 (https=) 2017-03-30
JP6669500B2 JP6669500B2 (ja) 2020-03-18

Family

ID=50290260

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015559038A Expired - Fee Related JP6669500B2 (ja) 2013-02-25 2014-02-24 薬物耐性akt変異体を検出し治療するための方法及び組成物
JP2019088252A Pending JP2019176858A (ja) 2013-02-25 2019-05-08 薬物耐性akt変異体を検出し治療するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019088252A Pending JP2019176858A (ja) 2013-02-25 2019-05-08 薬物耐性akt変異体を検出し治療するための方法及び組成物

Country Status (11)

Country Link
US (2) US9994913B2 (https=)
EP (1) EP2959014B1 (https=)
JP (2) JP6669500B2 (https=)
KR (1) KR102182488B1 (https=)
CN (1) CN105247072B (https=)
AR (1) AR094873A1 (https=)
BR (1) BR112015020054A2 (https=)
CA (1) CA2901126C (https=)
MX (1) MX369175B (https=)
RU (1) RU2015140573A (https=)
WO (1) WO2014130923A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901126C (en) 2013-02-25 2022-01-25 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
WO2015198144A2 (en) 2014-06-27 2015-12-30 Techflux, Ltd. Method and device for transmitting data unit
EP3380097A2 (en) * 2015-08-28 2018-10-03 Novartis AG Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017078752A1 (en) * 2015-11-06 2017-05-11 The Penn State Research Foundation Compositions and methods relating to cancer
CN112640031B (zh) * 2018-08-13 2023-10-03 塞莫费雪科学(不来梅)有限公司 同位素质谱法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE161850T1 (de) 1989-07-19 1998-01-15 Connetics Corp T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1736554B1 (en) 1996-05-29 2013-10-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
AUPO903897A0 (en) 1997-09-08 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Organic boronic acid derivatives
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008049022A2 (en) * 2006-10-18 2008-04-24 Translational Genomics Research Institute Methods for detection of cancer
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
WO2009103790A2 (en) * 2008-02-21 2009-08-27 Universite Libre De Bruxelles Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
EP3617330B1 (en) * 2011-04-01 2023-12-27 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
RU2015127037A (ru) * 2012-12-07 2017-01-11 Дзе Дженерал Хоспитал Корпорейшн Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
CA2901126C (en) 2013-02-25 2022-01-25 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant

Similar Documents

Publication Publication Date Title
Mitra et al. Novel delivery approaches for cancer therapeutics
Newell et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Lv et al. miRNA expression patterns in chemoresistant breast cancer tissues
AU2014282179B2 (en) Method for predicting therapeutic efficacy of PI3K/AKT/mTOR inhibitor on basis of PHLDA1 or PIK3C2B expression
JP2016510591A5 (https=)
JP2016533366A5 (https=)
Shah et al. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
Alegre et al. Circulating biomarkers in malignant melanoma
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
JP2017503481A5 (https=)
NZ627864A (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
HK1223795A1 (zh) 拉喹莫德响应性的基因表达生物标志物
WO2014036387A3 (en) Methods for diagnosis and treatment of cancer
WO2014144121A3 (en) Classification and actionability indices for lung cancer
EA201691257A1 (ru) Молекулярно-диагностический тест на рак
WO2013074676A3 (en) Assays for selecting a treatment regimen for a subject with depression and methods for treatment
JP2015504847A5 (https=)
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
WO2011088149A3 (en) Methods for predicting response of triple-negative breast cancer to therapy
Gettinger et al. A decade of advances in treatment for advanced non–small cell lung cancer
HK1213946A1 (zh) 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法
WO2014152777A3 (en) Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
JP2016537010A5 (https=)